Lab & Pathology Information Systems · Healthcare & Life Sciences
Should you build or buy Laboratory Information System (LIS/LIMS)?
Laboratory Information System (LIS/LIMS) software manages the end-to-end workflow of a laboratory — from test ordering and specimen tracking through result validation, QC management, and regulatory reporting. It handles instrument interfacing, chain-of-custody documentation, and accreditation compliance requirements that clinical and research labs depend on for daily operation.
The build-vs-buy decision for Laboratory Information System (LIS/LIMS) turns on how much validated compliance infrastructure your team can realistically maintain in-house and how far your workflow customization needs exceed what vendors already encode; the specifics — lab type, GxP obligations, and where AI fits your competitive model — decide it.
Build it, buy it, or bridge?
When building makes sense
Building a LIS/LIMS from scratch is defensible primarily at research laboratories where GxP validation requirements don't apply and the workflow is narrow enough to fit on an open-source platform like SENAITE or a custom application. In those environments, the regulatory documentation burden that makes clinical builds cost-prohibitive simply isn't present. The AI angle also opens a legitimate build path: result interpretation tools, QC anomaly detection, and outreach routing analytics are all tractable engineering projects that can run against LIS data exports or APIs. For labs where the AI layer is genuinely proprietary — think novel biomarker detection or institution-specific clinical decision support — owning that integration point has real strategic value. The key distinction is whether you're trying to build the operational backbone or the intelligence layer that sits above it. Building the backbone means taking on instrument interfacing, audit trails, and accreditation compliance that vendors have spent decades encoding; building the AI layer above a purchased backbone avoids that entirely.
When buying makes sense
Buying a LIS/LIMS is the sensible call for any laboratory operating under CLIA or CAP accreditation requirements — which covers essentially every clinical lab in the US. The 200-plus analyzer instrument interfaces that platforms like Clinisys and SCC Soft Computer carry represent years of direct negotiation with instrument manufacturers on proprietary communication protocols. That work isn't independently replicable in any reasonable timeframe. Beyond instrumentation, the GAMP Category 5 validation documentation required for regulated clinical systems means a self-built system faces an audit burden that tends to end the build conversation before it starts. LabVantage and Orchard Software also carry continuously updated reference range libraries, QC rule sets, and accreditation checklists that would require dedicated staff to maintain independently. For a hospital or reference lab where the LIS is mission-critical infrastructure running around the clock, a vendor's proven uptime record and support contracts matter as much as feature coverage. The buy case holds until a lab's differentiation needs genuinely exceed what vendor configuration can accommodate.
The desk read
LIS and LIMS platforms sit at the intersection of instrument integration and regulatory compliance in a way that makes them among the harder software categories to replicate in-house. Instrument interfacing via HL7 and ASTM protocols, chain-of-custody specimen tracking, and CLIA and CAP accreditation requirements are not problems with clean algorithmic solutions. They reflect decades of vendor negotiation with instrument manufacturers and accrediting bodies. LabVantage and Sunquest carry that embedded domain knowledge as a cost of their product.
The build case exists at research labs where GxP validation is not a requirement and where the workflow is narrow enough to fit an open-source platform like SENAITE. AI is beginning to touch result interpretation and quality control anomaly detection in ways that could eventually change this calculus, but those capabilities are more likely to land as modules extending existing platforms than as reasons to replace Orchard Software or NovoPath outright. For clinical labs operating under GAMP Category 5 requirements, the validation documentation burden alone tends to end the build conversation before it starts.
Frequently asked
What is Laboratory Information System (LIS/LIMS)?
Laboratory Information System (LIS/LIMS) software manages the end-to-end workflow of a laboratory — from test ordering and specimen tracking through result validation, QC management, and regulatory reporting. It handles instrument interfacing, chain-of-custody documentation, and accreditation compliance requirements that clinical and research labs depend on for daily operation.
When does building Laboratory Information System (LIS/LIMS) make sense?
Building makes the most sense at research labs without GxP obligations and narrow enough workflows to fit open-source tooling, or for teams building AI-driven interpretation and analytics layers on top of an existing LIS data foundation rather than replacing the operational core.
When does buying Laboratory Information System (LIS/LIMS) make sense?
Buying is the practical choice for clinical labs under CLIA or CAP accreditation requirements, where the instrument integration library, regulatory documentation burden, and 24/7 operational reliability expectations make self-builds cost-prohibitive and high-risk.
What are the main Laboratory Information System (LIS/LIMS) vendors?
Representative vendors include Orchard Software, Sunquest, LabVantage, NovoPath. B4 Pro scores the full set.
What is the difference between a LIS and a LIMS?
A Laboratory Information System (LIS) typically refers to clinical lab platforms focused on patient test ordering, results, and regulatory compliance. A Laboratory Information Management System (LIMS) is more common in research and industrial labs, emphasizing sample tracking, experiment management, and data integrity. The distinction has blurred significantly as vendors serve both markets.